Hepatitis C Conference Archive – 2017

New and Emerging Treatment of NASH

Saturday, April 29 •  9am – 1pm

The Carriage House • 25 S. Pitney Road • Galloway, NJ 08205

Free Conference • 2.5 CME’s


Chronic liver disease, including the disease resulting from Hepatitis C viral infection, comprises the 12th leading cause of death in the United States across all population groups, with total deaths of 36,427 (11.5/100,000 population) annually. Recent advances and refinements in the treatment of HCV and NASH are the subjects of this important conference. The 5th Annual Hepatitis C Conference will address current research and clinical developments in the diagnosis and treatment of HCV/ NASH with an overall goal of increasing the knowledge and competence of physicians and allied medical personnel in providing optimal care for patients with these conditions.

Learning Objectives

  • Upon completion of “New and Emerging Treatments for NASH“, participants should be able to discuss the basic principles of drug resistance, to describe relevant resistance profiles for each class of direct-acting antiviral agents (DAAs), and to select appropriate management approaches to avoid virologic failure resulting from pre-existing or emergent associated variants (RAVs).
  • Upon completion of “The Reality of a Live Donor Liver Transplantation“, participants should be able to understand the issues involved in living donor liver transplantation.
  • Upon completion of “Clinical Insights into the Management of Primary Biliary Cholangitis (PBC)“, participants should be able to examine current and emerging data relating to PBC diagnosis and develop evidence-based treatment plans for patients with PBC using the latest clinical evidence.       As well as identify disease-related symptoms and long-term medical management strategies to improve patient quality of life.

Target Audience

This activity is designed for physicians in the practice of hepatology, gastroenterology, and surgery as well as allied medical personnel, including nurses, nurse practitioners, and physician assistants involved in the diagnosis and management of chronic liver disease, including Hepatitis C and NASH.

Method of Participation

To meet the learning objectives and receive continuing education credits, participants are expected to check in at the registration desk, attend the program in person, and complete an online evaluation form at the conclusion of the activity. A letter certifying attendance and credit verification will be emailed to participants upon completion of the online evaluation survey.

Conference Parking

The Carriage House has ample space to park located right on the property.


The University of Nebraska Medical Center accredits this live activity for a maximum of 1 AMA PRA Category 1 Credits™. The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim credits that are commensurate with the extent of their participation in the activity.


Paul J. Gaglio, MD FACP, AGAF, FAASLD,

Paul J. Gaglio, MD FACP, AGAF, FAASLD, director of Hepatology Outreach at NY-Presbyterian Hospital, Columbia University Medical Center, is the former medical director of Adult Liver Transplantation at The Montefiore Medical Center.

Dr Gaglio received his bachelor’s in Biology/Physiology from Rutgers College in New Brunswick, NJ, and his MD from UMDNJ-New Jersey Medical School. He completed an internship and residency at Mount Sinai Medical Center in New York City, and a digestive disease/liver transplantation fellowship at New Jersey Medical School.

Dr. Gaglio has published multiple manuscripts, book chapters, and abstracts, and has participated in numerous research trials related to the therapy of hepatitis B and C, liver transplantation, and treatment of liver failure. He has lectured nationally and internationally on these topics.

His research interests include treatment of hepatitis B and C, the natural history of hepatitis C in liver transplant recipients, and non-alcoholic fatty liver disease.

John Santoro, DO, FACG, FACOI, FAGA, ASGE,

John Santoro, DO, FACG, FACOI, FAGA, ASGE, Director of Atlantic Gastroenterology Associates Hepatitis Treatment Center and currently serves as Governor of the Board of Directors for the state of New Jersey. He was elected by the  American College of Gastroenterology’s (ACG) more than 12,000 GI professionals in the U.S. and worldwide.

Dr. Santoro has published over 100 clinical studies, is Chief Attending physician at AtlantiCare Regional Medical Center, Atlantic City and Pomona, NJ, and past president of the medical staff at Shore Medical Center, Somers Point, NJ. He is a sought after speaker for national and international medical conferences and author of numerous articles on Hepatitis C. He has cared for more than 300,000 patients during his 34-year tenure at AGA and at affiliated medical centers.

Andrew Alloy, DO, FACOI

Andrew Alloy, DO, FACOI, is associated with Advanced Gastrointestinal Associates, Washington Township, NJ. He also serves as an Associate Professor of Clinical Medicine at Rowan University School of Osteopathic Medicine. He’s been in practice since 1983.

In June 2015, Dr. Alloy was the recipient of a live liver transplant. His son Michael was his donor.
Michael Alloy is 29 and lives in Brookline, Massachusetts. He is an Internet technologist and systems project coordinator and is currently studying for his Master’s degree at Boston University.


8:30 – 9:00 Registration

9:00 – 9:45 New and Emerging Treatments for NASH

  • Paul J. Gaglio, MD,
  • Professor of Medicine, New York Presbyterian Hospital/Columbia University Medical Center

9:45 – 10:30 Break

10:30 – 11:15 The Reality of a Live Donor Liver Transplantation

  • Andrew Alloy, DO
  • Gastroenterologist, Advanced Gastrointestinal Specialists, P.C.

11:15 – 12:00 Clinical Insights into the Management of Primary Biliary Cholangitis (PBC)

  • John Santoro, DO
  • Director of Atlantic Gastro Hepatitis Treatment Center, Egg Harbor Township, NJ

12:00 – 12:30 >&A